治疗中期18F-FDG PET显像中腮腺变化与放射性口干相关
研究纳入两项前瞻性影像生物标志物研究的56例头颈部鳞癌放疗患者,于基线和放疗第3周行FDG-PET/CT,计算同侧和对侧腮腺SUVmedian的绝对与相对变化,并与6个月时中度至重度口干(CTCAE≥2级)相关。29例(51.8%)发生≥2级口干,同侧腮腺ΔSUVmedian升高(p=0.04)和对侧腮腺平均剂量(p=0.04)与口干相关;将同侧腮腺ΔSUVmedian加入临床模型后预测效能最高(AUC 0.777,AIC 65.4)。
要点
- 56例头颈部鳞癌放疗患者中29例(51.8%)在6个月时发生CTCAE≥2级口干。
- 放疗第3周同侧腮腺SUVmedian较基线升高8.4%,对侧升高5.5%。
- 同侧腮腺ΔSUVmedian(p=0.04)与对侧腮腺平均剂量(p=0.04)与口干相关。
核心结论
- 研究显示放疗早期腮腺即发生功能变化,将基线与治疗中期FDG-PET/CT腮腺变化与临床因素结合可能改善口干风险预测,可用于个体化头颈部放疗。
研究设计与样本
- 研究纳入来自两项前瞻性影像生物标志物研究的56例接受放疗的黏膜头颈部鳞状细胞癌患者,在基线和放疗期间(第3周)行FDG-PET/CT,对双侧腮腺进行体积勾画并计算SUVmedian。
主要发现
- 29例(51.8%)在6个月时发生CTCAE≥2级口干。
- 与基线相比,第3周同侧腮腺SUVmedian升高8.4%,对侧腮腺SUVmedian升高5.5%。
- 同侧腮腺ΔSUVmedian(p=0.04)和对侧腮腺平均剂量(p=0.04)与口干相关。
- 参考「临床」模型与口干相关(AUC 0.667,AIC 70.9);将同侧腮腺ΔSUVmedian加入临床模型后与口干相关性最高(AUC 0.777,AIC 65.4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to measure functional changes in parotid glands using mid-treatment FDG-PET/CT and correlate early imaging changes to subsequent xerostomia in mucosal head and neck squamous cell carcinoma patients undergoing radiotherapy. MATERIALS AND METHODS: 56 patients from two prospective imaging biomarker studies underwent FDG-PET/CT at baseline and during radiotherapy (week 3). Both parotid glands were volumetrically delineated at each time point. PET parameter SUVmedian were calculated for ipsilateral and contralateral parotid glands. Absolute and relative change (Δ) in SUVmedian were correlated to moderate-severe xerostomia (CTCAE grade ≥ 2) at 6 months. Four predictive models were subsequently created using multivariate logistic regression using clinical and radiotherapy planning parameters. Model performance was calculated using ROC analysis and compared using Akaike information criterion (AIC) RESULTS: 29 patients (51.8%) developed grade ≥ 2 xerostomia. Compared to baseline, there was an increase in SUVmedian at week 3 in ipsilateral (8.4%) and contralateral (5.5%) parotid glands. Increase in ipsilateral parotid Δ SUVmedian (p = 0.04) and contralateral mean parotid dose (p = 0.04) were correlated to xerostomia. The reference 'clinical' model correlated to xerostomia (AUC 0.667, AIC 70.9). Addition of ipsilateral parotid Δ SUVmedian to the clinical model resulted in the highest correlation to xerostomia (AUC 0.777, AIC 65.4). CONCLUSION: Our study shows functional changes occurring in the parotid gland early during radiotherapy. We demonstrate that integration of baseline and mid-treatment FDG-PET/CT changes in the parotid gland with clinical factors has the potential to improve xerostomia risk prediction which could be utilised for personalised head and neck radiotherapy.
引用
- Trada Y, Lee MT, Jameson MG, et al. Mid-treatment 18F-FDG PET imaging changes in parotid gland correlates to radiation-induced xerostomia. Radiother Oncol. 2023. PMID: 37330056. doi:10.1016/j.radonc.2023.109745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。